Indian Drug Makers Succeed In Reducing R&D Costs
This article was originally published in PharmAsia News
Six of India's pharmaceutical makers have been successful in trimming research costs recently by separating new-drug development operations from their generic and domestic operations. Lupin, Sun Pharmaceuticals and Wockhardt reduced their research costs by 5.8 percent of operating income in the first quarter of this year. Dr Reddy's, Nicholas Piramal and Ranbaxy Laboratories also have been able to reduce their research costs compared with the same quarter of last year. (Click here for more
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.